GHK-Cu Dosing and Administration
There are no established FDA-approved dosing guidelines for GHK-Cu in humans, as it is not currently approved as a pharmaceutical agent for systemic administration. The evidence provided consists entirely of preclinical animal studies and cosmetic applications, with no validated human dosing protocols for therapeutic use.
Critical Evidence Gap
The provided "FDA Drug Label" references 1 are actually for flecainide (an antiarrhythmic medication), not GHK-Cu. This appears to be a data error. No legitimate FDA-approved drug label exists for systemic GHK-Cu administration.
Available Preclinical Data
Research studies provide only animal model dosing that cannot be directly extrapolated to human use:
Animal Studies (Not Human-Validated)
- Intranasal delivery: 15 mg/kg daily for 8 weeks in aged mice improved cognitive function 2, 3
- Intraperitoneal injection: 15 mg/kg for 5 days in mice showed transient cognitive effects 2
- Pulmonary fibrosis model: 0.2-20 μg/g/day intraperitoneally on alternate days 4
- ACL reconstruction model: Intra-articular injections of 0.3-3 mg/ml weekly for 4 weeks 5
Physiological Context
- Endogenous human serum GHK levels: ~200 ng/ml at age 20, declining to ~80 ng/ml by age 60 6
- This represents nanogram quantities, vastly lower than experimental animal doses
Copper Safety Considerations
Copper toxicity is a genuine concern that must be addressed before any systemic GHK-Cu administration:
Monitoring Requirements (Based on Copper Guidelines)
Per ESPEN guidelines 7:
- Baseline assessment: Measure serum copper, ceruloplasmin, and 24-hour urinary copper
- Deficiency threshold: Plasma copper <12 μmol/L with CRP >20 mg/L suggests deficiency
- Toxicity risk: Copper supplementation requires careful monitoring due to potential nephrotoxicity, hepatotoxicity, and organ failure 8
Contraindications
Based on Wilson's disease management principles 9, 10, 11:
- Absolute contraindication: Any copper metabolism disorder (Wilson's disease, Menkes syndrome)
- Relative contraindications: Hepatic dysfunction, cholestasis (impairs copper excretion)
- Monitoring for toxicity: Kayser-Fleischer rings, elevated free copper, liver enzyme abnormalities
Clinical Reality
No validated human dosing protocol exists for systemic GHK-Cu administration. The peptide is currently used only in:
- Topical cosmetic formulations (concentrations typically 0.05-2%)
- Research settings under controlled protocols
If Considering Off-Label Use
Any systemic administration would require:
Pre-treatment evaluation:
- Serum copper and ceruloplasmin levels
- Liver function tests (AST, ALT, bilirubin, albumin)
- Renal function (creatinine, eGFR)
- 24-hour urinary copper excretion
- Slit-lamp examination if copper metabolism disorder suspected
Monitoring during treatment:
- Monthly copper levels and liver function for first 3 months
- Quarterly monitoring thereafter
- Immediate discontinuation if urinary copper >1.6 μmol/24h or liver enzymes elevate 7
Dose considerations (purely theoretical, not validated):
- Human equivalent dose from mouse studies (~15 mg/kg) would be approximately 1.2 mg/kg using standard conversion factors
- For a 70 kg adult: ~84 mg daily
- This is speculative and not evidence-based for human use
Common Pitfalls
- Assuming animal doses translate directly: Pharmacokinetics, metabolism, and toxicity profiles differ substantially between species
- Ignoring copper burden: GHK-Cu delivers copper systemically; cumulative copper exposure must be monitored
- Overlooking drug interactions: Zinc supplementation interferes with copper absorption (8:1 to 15:1 zinc:copper ratio recommended) 12
- Inadequate monitoring: Copper toxicity can manifest as hemolysis, renal failure, or hepatic dysfunction 7, 8
Bottom line: Systemic GHK-Cu administration in humans lacks established dosing protocols, safety data, and regulatory approval. Any use beyond topical cosmetic applications should occur only within formal research protocols with appropriate ethical oversight and safety monitoring.